Tyra Biosciences (NASDAQ:TYRA) Posts Earnings Results, Misses Estimates By $0.07 EPS

Tyra Biosciences (NASDAQ:TYRA) announced its quarterly earnings results on Tuesday. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.07), FiscalAI reports.

Tyra Biosciences Trading Down 5.0%

TYRA traded down $1.10 during trading on Tuesday, reaching $21.20. The stock had a trading volume of 219,053 shares, compared to its average volume of 889,833. The stock’s 50 day moving average is $22.12 and its two-hundred day moving average is $29.59. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of -8.86 and a beta of 0.65. Tyra Biosciences has a one year low of $13.83 and a one year high of $40.65.

Wall Street Analyst Weigh In

TYRA has been the topic of a number of research analyst reports. HC Wainwright reduced their price objective on shares of Tyra Biosciences from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, September 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $56.00 target price on shares of Tyra Biosciences in a research report on Tuesday, September 8th. Wedbush reaffirmed an “outperform” rating and set a $53.00 target price on shares of Tyra Biosciences in a research note on Thursday, September 10th. Oppenheimer reiterated an “outperform” rating and set a $40.00 price target (down from $50.00) on shares of Tyra Biosciences in a research report on Tuesday, September 22nd. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $50.00 price target on shares of Tyra Biosciences in a research report on Tuesday, October 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $47.20.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc is a clinical-stage biopharmaceutical company developing precision medicines for genetically defined diseases. Its research focuses on small-molecule therapies that target the fibroblast growth factor receptor (FGFR) family and related pathways, using a drug-discovery approach designed to address resistance and selectivity challenges.

The company’s pipeline includes TYRA-300, a selective FGFR3 inhibitor being studied for conditions including achondroplasia and urothelial cancer, and TYRA-200, an FGFR inhibitor being developed for certain cancers.